Sách chuyên ngành Y Dược: Bone Metastases: A Translational and Clinical Approach (Tiếp cận lâm sàng về tiến triển di căn xương)

D. KARDAMAKIS - V. VASSILIOU - E. CHOW

BONE METASTASES: A TRANSLATIONAL AND CLINICAL APPROACH

(TIẾP CẬN LÂM SÀNG VỀ TIẾN TRIỂN DI CĂN XƯƠNG)

PUBLISHER: SPRINGER (2009)

THÔNG TIN CHUNG:

Tên sách: Bone Metastases: A Translational and Clinical Approach (tạm dịch: Tiếp cận lâm sàng về tiến triển di căn xương).

Tác giả: D. Kardamakis - V. Vassiliou - E. Chow.

NXB: Springer (2009).

Thông số: 404 trang - 18 chương chính.

Ung thư xương là một trong những căn bệnh ung thư nguy hiểm, bệnh diễn tiến âm thầm và cướp đi sinh mạng của nhiều người; thông thường ung thư xương là do di căn từ các bộ phận ung thư khác. Cuốn sách này là những đúc kết kiến thức và kinh nghiệm sâu sắc nhất trong chẩn đoán và điều trị căn bệnh này, rất phù hợp đối với các học viên cũng như chuyên gia trong chuyên ngành có nhu cầu tiếp thu những kiến thức tiên tiến nhất. Sách bản đẹp, mục lục tự động, dung lượng nhỏ gọn, tương thích tốt với các thiết bị cầm tay.

TABLE OF CONTENTS (MỤC LỤC):

Part I Fundamental Concepts of Bone Metastases

1 BONE ANATOMY, PHYSIOLOGY AND FUNCTION

Vassiliki Tzelepi, Athanassios C. Tsamandas, Vassiliki Zolotaand Chrisoula D. Scopa

2 PATHOPHYSIOLOGY OF BONE METASTASES

G. David Roodman

3 ANGIOGENESIS AND BONE METASTASIS: IMPLICATIONS FOR DIAGNOSIS, PREVENTION AND TREATMENT

Pelagia G. Tsoutsou and Michael I. Koukourakis

4 NATURAL HISTORY, PROGNOSIS, CLINICAL FEATURES AND COMPLICATIONS OF METASTATIC BONE DISEASE

Vassilios Vassiliou, Edward Chow and Dimitrios Kardamakis

5 BONE BIOMARKERS IN RESEARCH AND CLINICAL PRACTICE

Janet E. Brown and Edward Chow

Part II Imaging Modalities

6 RADIOLOGIC EVALUATION OF SKELETAL METASTASES ROLE OF PLAIN RADIOGRAPHS AND COMPUTED TOMOGRAPHY

Christina Kalogeropoulou, Anna Karachaliou and Peter Zampakis

7 THE CONTRIBUTION OF NUCLEAR MEDICINE IN THE DIAGNOSIS OF BONE METASTASES

Andor W. J. M. Glaudemans, Marnix G. E. H. Lam, Niels C. Veltman, Rudi A. J. O. Dierckx and Alberto Signore

8 MAGNETIC RESONANCE IMAGING OF METASTATIC BONE DISEASE

Ekaterini Solomou, Alexandra Kazantzi, Odysseas Romanosand Dimitrios Kardamakis

Part III Therapeutic Strategies

9 RADIOTHERAPY AND BONE METASTASES

Jan W. H. Leer and Yvette M. Van der Linden

10 BIPHOSPHONATES IN THE MANAGEMENT OFMETASTATIC BONE DISEASE

Fred Saad and Arif Hussain

11 COMBINED RADIOTHERAPY AND BISPHOSPHONATES STATE OF ART

Vassilios Vassiliou and Dimitrios Kardamakis

12 BIPHOSPHONATES IN THE TREATMENT OF BONE METASTASES – OSTEONECROSIS OF THE JAW

Cesar Augusto Migliorati

13 SURGICAL MANAGEMENT OF BONE METASTASES

Markku Nousiainen, Cari M. Whyne, Albert J. M. Yee, Joel Finkelsteinand Michael Ford

14 THE ROLE OF CHEMOTHERAPY IN THE TREATMENT OF BONE METASTASES

Thomas Makatsoris and Haralabos P. Kalofonos

15 HORMONOTHERAPY OF BONE METASTASES

Konstantinos Kamposioras and Evangelos Briasoulis

16 RADIONUCLIDE THERAPY

Giovanni Storto

Part IV Assessment of Therapeutic Response

17 ASSESSMENT OF THERAPEUTIC RESPONSE

Orit Freedman, Mark Clemons, Vassilios Vassiliou, Dimitrios Kardamakis, Christine Simmons, Mateya Trinkaus and Edward Chow

18 OUTCOME MEASURES IN BONE METASTASES CLINICAL TRIALS

Amanda Hird and Edward Chow

INDEX

REFERENCES (TÀI LIỆU THAM KHẢO):

1. Watts NB (1999) Clinical utility of biochemical markers of bone remodeling. Clin Chem 45: 1359–1368

2. Mundy GR (2000) Structure and physiology of the normal skeleton. In: Rubens RD and Mundy GR (eds.) Cancer and the skeleton, Martin Dunitz, London, pp. 1–19

3. Baron R, Vignery A, and Horowitz M (1984) Lymphocytes, macrophages and the regulation of bone remodelling. In: Peck WA (ed.) Bone and mineral research, Elsevier, Amsterdam, pp. 175–243

4. Russell G (2001) Introduction: Bone metabolism and its regulation. In: Eastell R, Baumann M, Hoyle NR, and Wieczorek L (eds.) Bone markers: Biochemical and clinical perspectives, London, Martin Dunitz

5. Krane SM (2005) Identifying genes that regulate bone remodeling as potential therapeutic targets. J Exp Med 201: 841–843

6. Fohr B, Dunstan CR, and Seibel MJ. Clinical review 165: Markers of bone remodeling in metastatic bone disease. J Clin Endocrinol Metab 88: 5059–5075

7. Coleman RE, Brown JE, Terpos E, et al. (2008) Prognostic value of bone markers in matastatic bone disease: Clinical evidence and future directions. Cancer Treat Rev 34: 629–639

8. Kingsley LA, Fournier PJR, Chirgwin D, et al. (2007) Molecular biology of bone metastases. Mol Cancer Ther 6: 2609–2617

9. Guise TA, Mohammad KS, Clines G, et al. (2006) Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 12: 6213–6216

10. Roodman DG and Dougall WC (2008) RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev 34: 92–101

11. Ebeling PR (2001) Potential candidates for bone turnover markers – N-telopeptide crosslinks of type I collagen (NTX). In: Eastell R, Baumann M, Hoyle NR, andWieczorek L (eds.) Bone markers: Biochemical and clinical perspectives, Martin Dunitz, London, pp. 28–38.

12. Brandt J, Frederiksen JK, Jensen CH, et al. (2001) The N-and CƯterminal propeptides of human procollagen type 1 (PINP and PICP): Molecular heterogeneity and assay technology. In: Eastell R, Baumann M, Hoyle NR, and Wieczorek L (eds.) Bone Markers: Biochemical and clinical perspectives, Martin Dunitz, London, pp. 73–81

13. Terpos E, Politou M, and Rahemtulla A (2005) The role of markers of bone remodeling in multiple myeloma. Blood Rev 19: 125–142

14. Brasso K, Christensen IJ, Johansen JS, et al. (2006) Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate 66: 503–513

15. Jung K, Lein M, Stephan C, et al. (2004) Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: Diagnostic and prognostic implications. Int J Cancer 11: 783–791

16. Demers LM (2001) Bone-specific alkaline phosphatase. In: Eastell R, Baumann M, Hoyle NR, and Wieczorek L (eds.) Bone markers: Biochemical and clinical perspectives, Martin Dunitz, London, pp. 57–63

17. Gundberg CM (2001) Osteocalcin. In: Eastell R, Baumann M, Hoyle NR, and Wieczorek L (eds.) Bone markers: Biochemical and clinical perspectives, Martin Dunitz, London, pp. 65–72

18. Koizumi M, Maeda H, Yoshimura K, et al. (1997) Dissociation of bone formation markers in bone metastasis of prostate cancer. Br J Cancer 75: 1601–1604

19. Ivaska KK, Kakonen S-M, Gerdhem P, Obrant KJ, Pettersson K, and Vaananen HK (2005) Urinary osteocalcin as a marker of bone metabolism. Clin Chem 51: 618–628.

20. Campbell FC, Blamey RW, Woolfson AMJ, et al. (1983) Calcium excretion CaE in metastatic breast cancer. Br J Surg 70: 202–204

21. Clarke NW, Holbrook IB, McClure J, et al. (1991) Osteoclast inhibition by pamidronate in metastatic prostate cancer: A preliminary study. Br J Cancer 63: 420–423

22. Peacock M, Robertson WG, and Nordin BE (1969) Relation between serum and urinary calcium with particular reference to parathyroid activity. Lancet 1: 384–386

23. Coleman RE, Mashiter G, Fogelman I, et al. (1988) Osteocalcin: A marker of metastatic bone disease. Eur J Cancer 24: 1211–1217

24. Vinholes J, Coleman R, and Eastell R (1996). Effects of bone metastases on bone metabolism: Implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat Rev 22: 289–331

25. Pecherstorfer M, Zimmer-Roth I, and Schilling T (1995) The diagnostic value of urinary pyridinium crosslinks of collagen, serum, total alkaline phosphatase and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metabol 80: 97–103

26. Vinholes JJ, Guo CƯY, Purohit OP, et al. (1996) Metabolic effects of pamidronate in patients with metastatic bone disease. Br J Cancer 73: 1089–1095

27. Gasser A, Celada A, Courvoisier B, et al. (1979) The clinical measurement of urinary total hydroxyproline excretion. Clin Chim Acta 95: 487–491

28. Deacon AC, Hulme P, Hesp R, et al. (1987) Estimation of whole body bone resorption rate: A comparison of urinary total hydroxyproline excretion with two radioisotopic tracer methods in osteoporosis. Clin Chim Acta 166: 297–306

29. Eyre DR, Koob TJ, and Van Ness KP (1984) Quantitation of hydroxpyridinium crosslinks in collagen by high performance liquid chromatography. Anal Biochem 137: 380–388

30. Coleman RE (1998) Monitoring of bone metastases. Eur J Cancer 34: 252–259

31. Calvo MS, Eyre DR, and Gundberg CM (1996) Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev 17: 333–368

32. Hannon RA, Sacco-Gibson N, Mallinak N, et al. (1999) Comparison of ELISA and direct response device to measure urinary type 1 collagen N-telopeptide (NTX) In postmenopausal women. Arthritis Rheum 42: S₂90

33. Hannon RA, Branton R, Percival DA, et al. (1998) Comparison of measurement of urinary crosslaps by osteosal, a rapid point of care test and by ELISA. J Bone Miner Res 23: S₆30

34. Garnero P, Gineyts E, Riou JP, et al. (1994) Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 79: 780–785

35. Leary TE (2001). CƯtelopeptides. In: Eastell R, Baumann M, Hoyle NR, and Wieczorek L (eds.) Bone markers: Biochemical and clinical perspectives, Martin Dunitz, London, pp. 39–48

36. Aruga, A., Kolzumi, M., Hotta, R, et al. (1997) Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer. Br J Cancer 76: 760–764

37. Elomaa I, Virkkunen P, Risteli L, et al. (1992) Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) Is a useful prognostic indicator in multiple myeloma. Br J Cancer 66: 337–341

38. Jakob C, Zavrski I, Heider U, et al. (2003) Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography. Clin Cancer Res 9: 3047–3051

39. Sassi ML, Eriksen H, Risteli L, et al. (2000) Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: Loss of antigenicity by treatment with cathepsin K. Bone 26: 367–373

40. Robins SP, Woitge H, Hesley R, et al. (1994) Direct enzyme linked-immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Min Res 9: 1643–1649

41. Seyedin SM, Kung VT, Daniloff YN, et al. (1993) Immunoassay for urinary pyridinoline: The new marker of bone resorption. J Bone Miner Res 8: 635–641

42. Gomez B, Ardakani S, Evans B, et al. (1996) Monoclonal antibodies assay for free urinary pyridinium cross-links. Clin Chem 42: 1168–1175

43. Fedarko NS, Jain A, Karadag A, Van Eman MR, et al. (2001) Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7: 4060–4066

44. Woitge HW, Pecherstorfer M, Horn E, et al. (2001) Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma. Br J Cancer 84: 344–351

45. Diel IJ, Solomayer EF, Siebel MJ, et al. (1999) Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin Cancer Res 5: 3914–3919

46. Lacey DL, Timms E, Tan HL, et al. (1998) Osteoprotogerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165–176.

47. Martin TJ, Danks JA, and Henderson MA (2005) Parathyroid hormone-related protein and bone metastases. In: Jasmin C, Coleman RE, Coia LR, Capanna R and Saillant G (eds.) Textbook of bone metastases, John Wiley and Sons, Chichester, pp. 27–40

48. Honore P, Luger NM, Sabino AC, et al. (2000) Osteoprotogerin blocks bone cancer-induced skeletal destruction. Skeletal pain and pain-related neurochemical re-organisation of the spinal cord. Nat Med 6: 521–528

49. Khosla S (2001) Minireview: The OPG/RANKL/RANK system. Endocrinology 142: 5050–5055

50. Dovio A, Data V, and Angeli A (2005) Circulating osteoprotogerin and soluble RANKL: Do they have a future in clinical practice? J Endocrinol Invest 28: 14–22

51. Rogers A and Eastell R (2005) Circulating osteoprotogerin and receptor activator for nuclear factor kappaB ligand: Clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 90: 6323–6331

52. Halleen JM (2003) Tartrate-resistant acid phosphatase 5B is a specific and sensitive marker of bone resorption. Anticancer Res 23: 1027–1029

53. Halleen JM, Ylipahkala H, Alatalo SL, et al. (2002) Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density. Calcif Tissue Int 71: 20–25

54. Korpela J, Tiitinen SL, Hiekkanen H, et al. (2006) Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer. Anticancer Res 26: 3127–3132

55. Chung YC, Ku CH, Chao TY, et al. (2006) Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment. Cancer Epidemiol Biomarkers Prev 15: 424–428

56. Ozu C, Nakashima J. Horiguchi Y, et al. (2008) Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer. Int J Urol 15: 419–422

57. Salminen EK, Kallioinen MJ, Ala-Houhala MA, et al. (2006) Survival markers related to bone metastases. Anticancer Res 26: 4879–4884

58. Hegele A, Wahl HG, Varga Z, et al. (2007) Biochemical markers of bone turnover in patients with localized and metastasized prostate cancer. BJU Int 99: 330–334

59. Jung K, Lein M, RingsdorfM, et al. (2006) Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma. J Urol 176: 1326–1331

60. Coombes RC, Dady P, Parsons C, et al. (1983) Assessment of response of bone metastases to systemic treatment in patients with breast cancer. Cancer 52: 610–614

61. Massidda B, Ionta MT, Foddi MR, et al. (1996) Usefulness of pyridinium crosslinks and CA 15–3 as markers in metastatic bone breast carcinoma. Anticancer Res 16: 2221–2224

62. Lipton A, Demers L, Daniloff Y, et al. (1993) Increased urinary excretion of pyridinium crosslinks in cancer patients. Clin Chem 39: 614–618

63. Walls J, Assiri A, Howell A, et al. (1999) Measurement of urinary collagen crosslinks indicate response to therapy in patients with breast cancer and bone metastases. Br J Cancer 80: 1265–1270

64. Garnero P, Buchs N, Zekri J, et al. (2000) Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 82: 858–864

65. Kanakis I, Nikolaou M, Pectasides D, et al. (2004) Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer. J Pharm Biomed Anal 34: 827–832

66. Brown JE, Cook RJ, and Major P (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97: 59–69

67. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, Saad F, Zheng M, Hei YJ, Seaman J, and Cook R (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23: 4925–4935.

68. Demers LM, Costa L, Chinchilli VM, et al. (1995) Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem 41: 1489–1494

69. Vinholes JJ, Coleman R, Lacombe, et al. (1999) Assessment of bone response to systemic therapy in an EORTC trial: Preliminary experience with the use of collagen cross-link excretion. Br J Cancer 80: 221–228

70. Body JJ, Dumon JC, Gineyts E, et al. (1997) Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy. Br J Cancer 75: 408–412

71. Garnero P (2001) Markers of bone turnover in prostate cancer. Cancer Treat Rev 27: 187–192

72. KoizumiM, Yonese J, Fukui I, et al. (2001) The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer and metastasis to bone. BJU Int, 87: 348–51

73. Berruti A, Panero A, Angelli A, et al. (1996) Different mechanisms underlying bone collagen resorption in patients with bone metastases from prostate and breast cancer. Br J Cancer 73: 1581–1587

74. Berruti A, Torta M, Piovesan A, et al. (1995) Biochemical picture of bone metabolism in breast cancer patients with bone metastases. Anticancer Res 15: 2871–2876

75. Costa L, Demers LM, Gouveia A, et al. (1999) Biochemical markers of bone turnover correlate with the extent of metastatic bone disease. Proc ASCO Abstr 18: 2375

76. Lipton A, Costa L, Suhail A, et al. (2001) Use of markers of bone turnover for monitoring bone metastases and the response to therapy. Semin Oncol 28: 54–59

77. Lipton A, Demers L, Curley E, et al. (1998) Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 34: 2021–2026

78. Ali SM, Demers LM, Leitzel K, et al. (2004). Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann Oncol 15: 455–459.

79. Abildgaard N, Brixen K, Kristensen JE, et al. (2003) Comparison of five biochemical markers of bone resorption in multiple myeloma: Elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy. Br J Haematol 120: 235–242

80. Brown JE, Thomson C, and Ellis S (2003). Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 89: 2031–2037

81. Hirsch V, Major P, Lipton A, et al. (2008) Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclasts activity. J Thorac Oncol 3: 228–236

82. Menssen HD, Sakalova A, Fontana A, et al. (2002) Effects of long term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 20: 2353–2359

83. Brown JE, McCloskey EV, Dewar JA, et al. (2007) The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease. Calcif Tissue Int 81: 341–351

84. Rosen LS, Gordon G, Kaminski M, et al. (2003) Long term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A double-blind, multicentre, comparative trial. Cancer 98: 1735–1744

85. Vinholes JJ, Purohit OP, Abbey ME, et al. (1997) Relationship between biochemical and symptomatic response in a double blind trial of pamidronate for metastatic bone disease. Ann Oncol 8: 1243–1250

86. Lipton A, Cook RJ, Major P, et al. (2007) Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclasts activity. Oncologist 12: 1035–1043

87. Lipton A, Cook R, Saad F, et al. (2008) Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 113: 193–201

88. Rivkin S (2006) Oral ibandronate versus intravenous zoledronic acid for breast cancer patients with skeletal complications: The swog trial. Bone 38: S₈2. Abstract 101

89. Generali D, Berruti A, Tampellini M, et al. (2007) The circadian rhthym of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load. Bone 40: 182–188

90. Generali D, Dovio A, Tampellini M, et al. (2008) Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases. Br J Cancer 98: 1753–1758.

91. Brown JE, Ellis S, Gutcher S, et al. (2002) The bone resorption marker NTX is strongly correlated with skeletal events in metastatic bone disease and is influenced by dose escalation of clodronate. Am Soc Clin Oncol 21: 385a

92. Brown JE, Ellis S, Gutcher S, et al. (2005) Using bone turnover markers to direct bisphosphonate therapy. Is this a feasible approach? Cancer Treat Reviews, 31: 44–57

93. Clemons M, Dranitsaris G, Ooi W, et al. (2006) Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol 24: 4895–4900

94. Clemons M, Dranitsaris G, Ooi W, et al. (2008) A phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) Or progressive bone metastases (BM) Despite standard bisphosphonates (BP) Therapy. Breast Cancer Res Treat 108: 79–85

95. Simmons C, Broom RJ, Cole DEC, et al. (2007) Urinary N-telopeptide is a rapid predictor of response to and palliative benefit from bisphosphonates therapy in patients with metastatic breast cancer. Support Cancer Ther 4: 182–187

96. US National Institutes of Health. Clinical trials: Randomized study of bone marker-directed schedule versus standard schedule of zoledronic acid in patients with advanced breast cancer metastatic to the bone. Available at http: // cancer. Gov/clinicaltrials/NCRI-BISMATK. Accessed October 31,2007

97. UK Clinical Research Network: Portfolio Database. Cost-effective use of BISphosphonates in metastatic bone disease – a comparison of bone MARKer directed zoledronic acid therapy to a standard schedule – the BISMARK trial. Available at pfsearch. Ukcrn. Org. Uk/ StudyDetail. Aspx? TopicID=1&StudyID=1737. Accessed October 31,2007

Download Ebook: BONE METASTASES: A TRANSLATIONAL AND CLINICAL APPROACH

========================